Physician profile
Navid Saigal
NPI 1427024231
$302,273.02
in general payments reported to CMS, 2019-2025
17 companies · $7,710 in 2025
The $7,710 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $26K · 2021: $68K · 2022: $75K · 2023: $41K · 2024: $30K · 2025: $7,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Travel and Lodging: $10K · Food and Beverage: $5,014 · Consulting Fee: $4,637 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,400 · Education: $39.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,826.00 |
| Travel and Lodging | $10,022.45 |
| Food and Beverage | $5,014.25 |
| Consulting Fee | $4,637.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,400.00 |
| Education | $39.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $170,806.65 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $56,269.10 | 2021-2023 | |
| Aurinia Pharma U.S., INC. | $28,273.48 | 2021-2022 | |
| Glaxosmithkline, LLC. | $19,305.24 | 2021-2024 | Jesduvroq, Benlysta |
| Akebia Therapeutics INC | $18,952.24 | 2019-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $5,405.23 | 2024 | Crit-Line, 2008t Bluestar Hemodialysis Machine |
| Travere Therapeutics, INC. | $1,260.97 | 2022-2025 | Filspari |
| Janssen Pharmaceuticals, INC | $784.00 | 2019-2025 | Spravato |
| Opko Pharmaceuticals, LLC | $565.03 | 2019-2025 | Rayaldee |
| Amgen INC. | $194.11 | 2019-2025 | Aranesp, Parsabiv, Tavneos |
| Horizon Therapeutics Plc | $124.99 | 2019 | |
| Lilly USA, LLC | $122.07 | 2024 | Jardiance |
| Vertex Pharmaceuticals Incorporated | $73.24 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $54.84 | 2019-2023 | Jynarque |
| Calliditas Therapeutics US INC. | $38.09 | 2023 | Tarpeyo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $26.69 | 2022 | |
| Ardelyx, INC. | $17.05 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navid Saigal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.